Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
Giorgio Frega, Fernando P. Cossío, Jesús M. Bañales, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2098-2098
Open Access | Times Cited: 19

Showing 19 citing articles:

Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives
B. Ten Haaft, Manuel Pedregal, J Prato, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113564-113564
Open Access | Times Cited: 19
New trends in diagnosis and management of gallbladder carcinoma
Efstathios Pavlidis, I. Galanis, T. Pavlidis
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 1, pp. 13-29
Open Access | Times Cited: 11
Unresectable biliary tract cancer: Current and future systemic therapy
Danmei Zhang, Klara Dorman, C. Benedikt Westphalen, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114046-114046
Open Access | Times Cited: 7
Changes in L‐phenylalanine concentration reflect and predict response to anti‐PD‐1 treatment combined with chemotherapy in patients with non‐small cell lung cancer
Yaqing Liu, Ping Yu, Liubo Zhang, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
The Search for Risk, Diagnostic and Prognostic Biomarkers of Cholangiocarcinoma and their Biological and Clinicopathological Significance
Rocı́o I.R. Macı́as, Hiroaki Kanzaki, Carmen Berasain, et al.
American Journal Of Pathology (2024)
Closed Access | Times Cited: 4
Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date
Michael H. Storandt, Zhaohui Jin, Amit Mahipal
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 383-394
Open Access | Times Cited: 2
Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and Strategies
Andrew Hall, Sarah Brown, Niharika B. Mettu, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 2
Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers
Jianan Jin, Haibo Mou, Yibin Zhou, et al.
Cancer Control (2024) Vol. 31
Open Access | Times Cited: 2
Second line chemotherapy for advanced biliary cancer: FOLFOX versus FOLFIRI: Analysis of retrospective and prospective data
I. V. Savchenko, И. С. Стилиди, I. А. Dzhanyan, et al.
Journal of Modern Oncology (2024) Vol. 26, Iss. 2, pp. 202-209
Open Access | Times Cited: 1
Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers
Tarık Demır, Carolyn Moloney, Devalingam Mahalingam
Critical Reviews in Oncology/Hematology (2024) Vol. 199, pp. 104388-104388
Closed Access | Times Cited: 1
CircRNome‐wide characterisation reveals the promoting role of circAATF in anti‐PD‐L1 immunotherapy of gallbladder carcinoma
Yueqi Wang, Shengli Li, Xiaobo Bo, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 10
Open Access | Times Cited: 1
Comparison of treatment models for single primary advanced gallbladder cancer
Rongxuan Li, Xiaohong Chen, Bingchen Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Changes in L-phenylalanine concentration is a risk factor for NSCLC patients who received PD-1 Ab treatment: a case-control study
Yaqing Liu, Ping Yu, Liubo Zhang, et al.
Research Square (Research Square) (2024)
Open Access
Immunotherapy
Layal Al Mahmasani, James J. Harding, Ghassan K. Abou‐Alfa
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 3, pp. 643-657
Closed Access
Prognostic nomogram for cholangiocarcinoma after immunotherapy
Chao Chen, Zhan Shi, Xiaoyuan Chu, et al.
Research Square (Research Square) (2024)
Open Access
The role of molecular diagnostics in the choice of therapy for biliary tract cancers
Natalia V. Mitiushkina, Evgeny N. Imyanitov
Siberian Journal of Oncology (2024) Vol. 23, Iss. 1, pp. 130-141
Open Access
Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies
Yidan Lou, Yijing Chen, Kaibo Guo, et al.
Biomarkers in Medicine (2024) Vol. 18, Iss. 15-16, pp. 703-715
Closed Access
Assessing the Prognostic Value of 13 Inflammation-Based Scores in Patients with Unresectable or Advanced Biliary Tract Carcinoma After Immunotherapy
Fang Wang, Chang Jiang, Wenzhuo He, et al.
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 541-557
Open Access
Clinical Updates for Gastrointestinal Malignancies
Carmelo Laface, Riccardo Memeo
Journal of Personalized Medicine (2023) Vol. 13, Iss. 9, pp. 1424-1424
Open Access | Times Cited: 1
Page 1

Scroll to top